International Stem Cell Corp. is inching closer to bringing its stem cell therapy for Parkinson's to the FDA in hopes of eventually reversing the disease's symptoms in people.
A protein previously known for other functions has also been found to act as a switch that decides whether an immature neural cell stays in a stem cell-like state or differentiates into a functional neuron.
A new therapeutic target involved in stimulating the growth of damaged brain cells could provide new ways to treat multiple sclerosis.
In a finding that could have implications for leukemia treatment, investigators at the University of California, San Diego School of Medicine have linked a protein associated with an important stem cell signal to cancer growth.
An international team of scientists has found a new way to create stem cells without the use of an embryo or outside DNA--an advance in stem cell technology that doesn't carry the ethical concerns of embryonic stem cells or the safety issues of induced pluripotent stem cells.
The California Institute for Regenerative Medicine is putting $40 million toward the creation of a new Center of Excellence in Stem Cell Genomics, which will bring together experts and investigators from 7 California institutions.
Johns Hopkins researchers have developed a safer way to make human iPS cells, and using these cells, they've successfully repaired damaged retinal vascular tissue in mice.
Knowing how to preserve human embryonic stem cells in their pluripotent state until they are needed will help scientists better harness these cells for use in a variety of therapies. Now researchers have identified a gene receptor and signaling pathway that plays an essential role in preserving hESCs in an undifferentiated state.
International Stem Cell Corp. has found a new way to genetically reprogram mature cells into an embryonic-like state, a technique the Carlsbad, CA-based company believes is a safer and more efficient way of creating induced pluripotent stem cells.
Using stem cell technology, Johns Hopkins researchers and collaborators at Isis Pharmaceuticals have developed several new compounds that seem to halt the toxic effects that lead to brain destruction in amyotrophic lateral sclerosis and dementia in lab studies.